Proteolysis targeting chimeras (PROTACs) technology is a novel and promising therapeutic
strategy using small molecules to induce ubiquitin-dependent degradation of proteins. It has …

Despite the success of targeted therapies in cancer treatment, therapy-induced resistance
remains a major obstacle to a complete cure. Tumor cells evade treatments and relapse via …

Epithelial-to-Mesenchymal Transition (EMT) has been shown to be crucial in tumorigenesis
where the EMT program enhances metastasis, chemoresistance and tumor stemness. Due …

Although many kinds of therapies are applied in the clinic, drug-resistance is a major and
unavoidable problem. Another disturbing statistic is the limited number of drug targets, which …

Proteolysis targeting chimeric (PROTAC) technology is an effective endogenous protein
degradation tool developed in recent years that can ubiquitinate the target proteins through …

Janus kinase-signal transducer and activator of transcription (JAK-STAT) signaling mediates
almost all immune regulatory processes, including those that are involved in tumor cell …

Prostate cancers are considered to be immunologically 'cold'tumors given the very few
patients who respond to checkpoint inhibitor (CPI) therapy. Recently, enrichment of …

Enhancers are genomic sequences that play a key role in regulating tissue-specific gene
expression levels. An increasing number of diseases are linked to impaired enhancer …

Proteolysis targeting chimera (PROTAC), hijacking protein of interest (POI) and recruiting E3
ligase for target degradation via the ubiquitin-proteasome pathway, is a novel drug …

Abstract Changes in the micro-environment of fibrous connective tissue can lead to
alterations in the phenotypes of tissue-resident cells, yet the underlying mechanisms are …